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Introduction: Podocalyxin (gene name PODXL) is a CD34-related sialomucin implicated in the regulation of cell
adhesion, migration and polarity. Upregulated expression of podocalyxin is linked to poor patient survival in
epithelial cancers. However, it is not known if podocalyxin has a functional role in tumor progression.
Methods: We silenced podocalyxin expression in the aggressive basal-like human (MDA-MB-231) and mouse (4T1)
breast cancer cell lines and also overexpressed podocalyxin in the more benign human breast cancer cell line,
MCF7. We evaluated how podocalyxin affects tumorsphere formation in vitro and compared the ability of
podocalyxin-deficient and podocalyxin-replete cell lines to form tumors and metastasize using xenogenic or
syngeneic transplant models in mice. Finally, in an effort to develop therapeutic treatments for systemic cancers,
we generated a series of antihuman podocalyxin antibodies and screened these for their ability
to inhibit tumor progression in xenografted mice.
Results: Although deletion of podocalyxin does not alter gross cell morphology and growth under standard
(adherent) culture conditions, expression of PODXL is required for efficient formation of tumorspheres in vitro.
Correspondingly, silencing podocalyxin resulted in attenuated primary tumor growth and invasiveness in mice
and severely impaired the formation of distant metastases. Likewise, in competitive tumor engraftment assays
where we injected a 50:50 mixture of control and shPODXL (short-hairpin RNA targeting PODXL)-expressing cells,
we found that podocalyxin-deficient cells exhibited a striking decrease in the ability to form clonal tumors in the
lung, liver and bone marrow. Finally, to validate podocalyxin as a viable target for immunotherapy, we screened
a series of novel antihuman podocalyxin antibodies for their ability to inhibit tumor progression in vivo. One of
these antibodies, PODOC1, potently blocked tumor growth and metastasis.
Conclusions: We show that podocalyxin plays a key role in the formation of primary tumors and distant tumor
metastasis. In addition, we validate podocalyxin as potential target for monoclonal antibody therapy to inhibit
primary tumor growth and systemic dissemination.* Correspondence: kelly@brc.ubc.ca
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Although most human cancers begin as primary focal
lesions, metastasis of these primary tumors to distant
sites heralds advanced stage disease, poor prognosis
and eventual patient death [1]. For this reason, bio-
markers that identify tumors likely to metastasize, and
the generation of therapeutics that can inhibit metasta-
sis, are key to improving patient survival. Although ad-
juvant therapies have been developed for several types
of breast tumors, triple-negative breast cancers (estro-
gen receptor (ER)-, progesterone receptor (PgR)- and
human epidermal growth factor receptor 2 (HER2)-
negative) are particularly challenging to treat because
of their highly aggressive nature and a lack of well-
defined therapeutic targets on these cells [2].
Podocalyxin (also known as PCLP1, MEP21, gp135,
TRA-1-60, TRA-1-81 and GCTM2) is a CD34-related
sialomucin and a well-known marker of embryonic stem
cells, embryonal carcinomas, neoplastic hematopoietic cells
[3-6] and a variety of normal cells during embryonic deve-
lopment, where it plays a key role in tissue morphogenesis
[7-9]. We previously showed that podocalyxin (gene name
PODXL) is upregulated on a subset of primary breast tu-
mors and is an independent predictor of progression, me-
tastasis and poor outcome [10]. Subsequent studies have
confirmed podocalyxin as a prognostic indicator of poor
outcome in a variety of malignancies, including ovarian,
prostate, renal, pancreatic, thyroid, glioblastoma, astrocy-
toma, colorectal and bladder cancers [10-18]. Ectopic ex-
pression of PODXL enhances tumor aggressiveness in vitro.
MCF7 breast tumor cells engineered to express high
levels of murine podocalyxin (MCF7Podxl) exhibit
increased migration in vitro, altered morphogenesis
and disrupted cell–cell and cell–matrix contacts
[10,19,20]. In addition, podocalyxin has been shown to
play a role in the control of cell migration and the ex-
pression of matrix metalloproteinases MMP1 and
MMP9 [17,21]. Collectively, these studies establish a
correlation between podocalyxin expression, tumor ag-
gressiveness and poor outcome (reviewed by McNagny
et al. [22]). However, the functional significance of
podocalyxin expression by primary tumors and its in-
fluence on metastatic progression in vivo have yet to be
thoroughly evaluated. In the present study, we have ad-
dressed this issue by silencing podocalyxin expression
in the highly aggressive triple-negative basal-like hu-
man breast cancer cell line, MDA-MB-231, or overex-
pressing it in a well-differentiated, ER-positive and
PgR-positive, luminal-like human breast cancer cell
line, MCF7 [23]. We found that podocalyxin is required
for efficient tumorsphere formation in both MCF7 and
MDA-MB-231 cells. Moreover, suppression of PODXL in
MDA-MB-231 cells profoundly impairs formation of
primary tumors and secondary metastasis in xenograftedmice. We recapitulated this finding in an immunocompe-
tent mouse tumor model by silencing podocalyxin expres-
sion in 4T1 cells (a mouse mammary tumor line) and
engrafting these cells in syngeneic BALB/c mice. Finally,
we developed a novel podocalyxin-specific monoclonal
antibody (mAb) that delays xenografted tumor formation
and metastatic disease in mice. These data validate podo-




MDA-MB-231, MCF7 and 4T1 cells (American Type Cul-
ture Collection, Manassas, VA, USA) were grown as mono-
layers on tissue culture-treated plastic plates. All cell lines
were maintained in low passage (<15). Both MDA-MB-231
and MCF7 human breast tumor cell lines were cultured in
Dulbecco’s modified Eagle’s medium (DMEM) supple-
mented with 10% fetal bovine serum (FBS), penicillin and
streptomycin. 4T1 BALB/c mouse-derived mammary tumor
cells were cultured in DMEM supplemented with 10% FBS,
2 mM glutamine, nonessential amino acids, penicillin and
streptomycin. All cell lines were cultured in a humidified 5%
CO2 incubator at 37°C.
Transduction
MDA-MB-231 cells were labeled with green fluorescent
protein (GFP) or red fluorescent protein (RFP) using retro-
viral vectors pLNCX2-GFP or pLNCX2-RFP, respectively
(Clontech Laboratories, Mountain View, CA, USA). Hu-
man PODXL was silenced in MDA-MB-231 cells by lenti-
viral infection using pLKO.1 containing either a scrambled
short-hairpin RNA (shRNA) (shCTRL) or a PODXL-target-
ing shRNA (RHS3979-9848792, shPODXL) as recom-
mended by the manufacturer (Dharmacon, Lafayette, CO,
USA). All cell lines were derived from pooled cultures of
infected cells. Cells were cultured under continuous drug
selection with puromycin (4 μg/ml; Invitrogen, Carlsbad,
CA, USA) and G418 (1 mg/ml; Calbiochem, San Diego,
CA, USA). PODXL-transfected MCF7 cells were described
previously [10,19]. Cells were cultured under continuous
selection with gentamicin (50 μg/ml; Calbiochem).
Predicted shRNA sequences to target murine 4T1 Podxl
were identified using pSicoOligomaker v1.5 freeware (http://
web.mit.edu/jacks-lab/protocols/pSico.html). Three individ-
ual shRNA oligomers were each cloned into the HpaI and
XhoI sites of the pLL3.7 lentiviral vector. Firefly luciferase-
expressing 4T1 (4T1-luc) cells were maintained under selec-
tion in G418 (400 μg/ml; Calbiochem). To produce lentiviral
particles, 293T cells were cotransfected with 10 μg of pLL3.7
and the appropriate packaging plasmids (3.5 μg of pVSVg,
3.5 μg of pRSV-Rev, 6.5 μg of pMDLgag/pol) by calcium
phosphate transfection. Lentivirus-containing media were
collected 36 hours post-transfection and transferred to
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containing medium was replaced with regular growth media
after 48 hours and incubated for an additional 48 hours.
The cells were then harvested for analysis of expression of
mouse podocalyxin RNA and protein. 4T1 cells with the
most efficient knockdown were used for all studies and cul-
tured with gentamicin (50 μg/ml; Calbiochem).Quantitative RT-PCR
RNA isolation was performed using TRIzol reagent (Life
Technologies, Carlsbad, CA, USA) according to the
manufacturer’s instructions. Total RNA (2 μg) was
reverse-transcribed using a high-capacity cDNA reverse
transcription kit (Life Technologies). Real-time quantitative
PCR was performed using a SYBR FAST qPCR kit (Kapa
Biosystems, Wilmington, MA, USA). The PODXL-specific
primers used were 5′-CTCACCGGGGACTACAACC-
3′ (forward) and 5′-GCCTCCTCTAGCCACGGTA-3′
(reverse). Relative expression of PODXL was determined
relative to GAPDH in each reaction.Tumorsphere assay
MDA-MB-231 and MCF7 cells were harvested, and
spheres were cultured in MammoCult™ medium (StemCell
Technologies, Vancouver, BC, Canada). After 7 days, tumor-
spheres larger than 60 μm in diameter were counted manu-
ally using a counting grid. Tumorsphere-forming efficiency
was calculated as follows: number of tumorspheres divided
by number of cells initially plated times 100.In vivo tumor growth and lung metastasis
For in vivo experiments, we used 6- to 12-week-old
female nonobese diabetic severe combined immunodefi-
ciency, interleukin 2 receptor gamma chain deficient,
NOD.Cg-PrkdcscidIl2rgtm1Wjl/SzJ (NSG) mice or BALB/cJ
mice (The Jackson Laboratory, Bar Harbor, ME, USA). Ani-
mals were maintained in a specific pathogen-free facility
at the University of British Columbia (UBC) Biomedical
Research Centre. All experiments were conducted with
approval of the UBC Animal Care Committee.
Primary tumor development was examined following
subcutaneous (s.c.) injection of MDA-MB-231 cells (1 ×
106) prepared in BD Matrigel™ (BD Biosciences, San
Jose, CA, USA) into the right hind flank of NSG mice.
Tumor growth was measured using manual calipers,
and the tumor volume was estimated using the follow-
ing formula: length times width2 divided by 2. Final
tumor masses were measured after excision and the
tumors were retained for histochemical analyses. Flow
cytometry was performed on lung digests to enumerate
tumor cells based on detection of GFP or RFP fluorescence.Competitive experimental metastases
To examine experimental metastasis, a 50:50 mixture of 0.5
to 2.0 × 105 shCTRLRFP (or shCTRLGFP) and shPODXLGFP
(or shPODXLRFP) MDA-MB-231 cells were resuspended in
100 μl of Hanks’ balanced salt solution and injected into
the tail vein of NSG mice. At day 3, 7 or 14 postinjection,
mice were killed using 2,2,2-tribromoethanol (Avertin;
Sigma-Aldrich, St Louis, MO, USA), then perfused through
the right ventricle with 10 ml of phosphate-buffered saline
(PBS) containing 2 mM ethylenediaminetetraacetic acid
(EDTA), and the lungs (and, in some experiments, liver, fe-
murs and tibias) were removed. Lungs were digested in col-
lagenase/dispase solution as described elsewhere [24], and
GFP-positive or RFP-positive tumor cells were detected by
flow cytometry. At 6 weeks postinjection, NSG mice were
killed and perfused as described above, but tumor nodules
on the surface of lungs and livers were manually counted
using a Leica Fluo™ dissecting microscope (Leica Microsys-
tems, Buffalo Grove, IL, USA) and QImaging™ software
(QImaging, Surrey, BC, Canada). In addition, lung, liver
and bone marrow cells were prepared as described previ-
ously and analyzed by flow cytometry.
Flow cytometry
Staining was performed with PBS containing 2% FBS, 2
mM EDTA and 0.05% sodium azide. MDA-MB-231 cells
were stained with a primary antibody (Ab) against podo-
calyxin (goat antihuman podocalyxin antibody (anti-
PODO Ab); R&D Systems, Minneapolis, MN, USA) or a
goat immunoglobulin G (IgG) isotype control (Iso) and
followed with a chicken anti-goat Alexa Fluor (AF) 647–
coupled secondary Ab (Molecular Probes, Eugene, OR,
USA) for 30 minutes at 4°C and analyzed using a BD
LSR II flow cytometer (BD Biosciences). Murine 4T1-luc
cells were labeled with allophycocyanin-conjugated rat
anti-mouse podocalyxin Ab (R&D Systems) and analyzed by
flow cytometry. Rat IgG2b was used as an isotype control.
Experimental lung metastasis
A total of 1 × 105 vector control (VC) or shPODXL 4T1-
luc cells were injected intravenously (i.v.) into the lateral tail
vein BALB/c mice. Lungs were perfused and excised as de-
scribed above. Tumor burden was assessed by counting
nodules visible on the surface of the lungs using a dissect-
ing microscope and then corroborated by performing a lu-
ciferase assay of homogenized lung tissue.
Luciferase enzymatic assay
Total luciferase activity was assayed from lungs harvested
from BALB/c mice injected i.v. with 4T1-luc cells. Lungs
were homogenized in cell lysis buffer (Promega, Madison,
WI, USA). Protein concentration was determined using a
Thermo Scientific Pierce bicinchoninic acid protein assay
kit (Pierce Biotechnology, Rockford, IL, USA). The Dual-
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detect luciferase activity. In these experiments, 20 μl of
sample supernatant was mixed with 50 μl of luciferase
assay reagent, and luciferase activity was quantified using
a SpectraMax L microplate reader (Molecular Devices,
Sunnyvale, CA, USA). The results are reported as relative
light units.
Therapeutic antibody production
New Zealand White rabbits were immunized with A-172
glioblastoma cells that express high levels of tumor-
glycosylated human podocalyxin on their cell surface. Rabbit
mAbs were rescued as previously described [25]. Briefly,
individual B-cell clones were isolated from animals whose
sera recognized MDA-MB-231 cell–expressed podocalyxin
extracellular domain by enzyme-linked immunosorbent
assay. Next, supernatants were screened against MDA-MB-
231 and human embryonic kidney 293 (HEK293) cells with
and without podocalyxin on their surface (both cell lines
express endogenous podocalyxin) to ensure immunoreactiv-
ity to the native protein and minimal nonspecific binding
to PODXL-deficient cells. Finally, supernatants were also
screened using Chinese hamster ovary (CHO) cells express-
ing podocalyxin and CD34 to ensure podocalyxin specificity.
By comparing binding selectivity for podocalyxin expressed
on tumor and normal cells, B-cell clones that produced Abs
with favorable binding profiles to tumor cells were selected
for cloning, scale-up production and in vivo screening.
Preclinical mouse model to assess anti-podocalyxin
therapeutic antibody efficacy
Candidate anti-PODO Abs were selected based on the level
of binding to known podocalyxin-expressing tumor cell
lines (Table 1). MDA-MB-231RFP tumor cells (1 × 106 cells)
were incubated with 25 μg of anti-PODO Ab (PODOC1
through PODOC8) or Iso Ab (anti-ovalbumin) at room
temperature for 30 minutes. Prior to injection, the tumor
cell/Ab mixture was diluted in Matrigel™ and injected s.c.
into the flank region of NSG mice. For systemic therapy,Table 1 Binding selectivity (geometric mean) of candidate po
mAb name HUVEC MCF7 MDA-MB-231 T47D
Isotype 489 657 477 697
PODOC1 44,611 60,805 91,909 1,498
PODOC2 3,231 1,962 26,513 2,036
PODOC3 2,103 9,399 2,939 818
PODOC4 113,144 15,161 143,135 34,559
PODOC5 40,490 25,055 80,312 1,853
PODOC6 994 1,239 4,744 2,685
PODOC7 21,700 22,330 57,626 1,010
PODOC8 23,207 45,707 1,950 566
aHEK293, Human embryonic kidney 293 cells; HUVEC, Human umbilical vascular endbeginning on day 14 after tumor injection, mice were
administered 100 μg of Ab (4.5 mg/kg) by intraperitoneal
(i.p.) injection twice weekly. Tumor dimensions were mea-
sured every 3 days until the mice were killed on day 27.
Histological analysis
Formalin-fixed, paraffin-embedded tumor specimens were
serially sectioned. Representative sections were deparaffi-
nized and stained with hematoxylin and eosin (H&E) or Ki-
67 Ab (1:700; Thermo Scientific, Waltham, MA, USA)
followed by donkey anti-rabbit AF488 secondary Ab (1:1,000;
Invitrogen). ProLong Gold Antifade mounting compound
with 4′,6-diamidino-2-phenylindole dihydrochloride (DAPI)
nuclear stain (Life Technologies) was used to mount slides.
H&E-stained sections were examined qualitatively for evidence
ofmuscular invasion and tumor border integrity.
Statistical analysis
Data are expressed as the mean ± standard error of the
mean (SEM) unless indicated otherwise. A Student’s
t-test was conducted for evaluation of statistical signifi-
cance. Data generated from time-dependent studies were
analyzed by two-way analysis of variance. P < 0.05 was
considered to be statistically significant. All data pre-
sented in the figures are representative of at least two in-
dependent experiments.
Results
Podocalyxin promotes tumorsphere formation in vitro
To examine the role of podocalyxin in tumor progression,
we silenced expression in MDA-MB-231 human breast can-
cer cells using a shRNA-containing lentivirus (shPODXL).
RFP- and GFP-labeled MDA-MB-231 cells were used as a
method for subsequent tracking of knockdown cells in vivo.
Gene expression analyses confirmed attenuated PODXL
expression in shPODXL cells (Figure 1A). In addition, flow
cytometric analyses confirmed that cell surface podocalyxin
expression is efficiently reduced in shPODXLGFP cells
(threefold decrease) compared with scrambled shRNA-docalyxin antibodies compared with isotype controla
CAOV-3 OVCAR-3 OVCAR-10 A-172 HEK293
767 629 653 644 446
48,817 16,502 2,834 169,600 28,225
37,683 9,189 645 49,862 459
10,472 8,355 1,803 181,211 3,869
125,223 29,862 564 333,980 2,679
31,657 9,824 1,756 172,233 27,144
1,670 1,350 1,165 2,760 485
37,668 11,058 2,539 278,032 13,886
52,200 8,805 2,731 263,842 5,056
othelial cells; mAb, Monoclonal antibody; PODOC, Podocalyxin antibody.
Figure 1 Podocalyxin promotes tumorsphere formation. (A) PODXL gene expression relative to GAPDH in scrambled shRNA (shCTRL) and shRNA
targeting PODXL (shPODXL) MDA-MB-231 cells as determined by quantitative PCR (n = 3; *P < 0.05; ***P < 0.001). (B) Podocalyxin expression on shCTRLGFP
cells (green fluorescent protein (GFP); solid green) and shPODXLGFP (dashed green) MDA-MB-231 cells (left histogram) and shCTRLRFP (red fluorescent protein
(RFP); solid red) and shPODXLRFP (dotted red) MDA-MB-231 cells (right histogram) relative to isotype control (shaded). RFI, Relative fluorescence intensity. (C)
Tumorsphere-forming efficiency of shCTRL (solid bar) and shPODXL (open bar) MDA-MB-231 cells cultured for 7 days under anchorage-independent
conditions (n = 3; **P < 0.01, ***P < 0.001). (D) Self-renewal capacity of shCTRLRFP (solid bars) and shPODXLRFP (open bars) MDA-MB-231 tumorspheres
assessed by serial passaging (P) (n = 3; ***P < 0.001 by one-way analysis of variance). (E) MCF7pIRES control (solid bar) and MCF7Podxl (open bar) cells
were cultured under anchorage-independent conditions for 7 days to assess tumorsphere-forming efficiency (n = 3; **P < 0.01). Figures are
representative of three experiments with similar results. Error bars indicate standard error of the mean.
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wise, podocalyxin expression in shPODXLRFP cells was
reduced by approximately twofold compared with
shCTRLRFP control (Figure 1B, right panel). Similarly,
total levels of podocalyxin protein were reduced in
shPODXL cells compared with control as shown by
Western blotting (Additional file 1).
Although proliferation of MDA-MB-231 cells in
monolayer culture was unaffected by silencing PODXL
(Additional file 2), the frequency of tumorsphere-
forming cells in three-dimensional assays was reduced by
more than threefold in shPODXL cultures (Figure 1C). The
comparable size (Additional file 3A, B) and morphologyof control and shPODXL tumorspheres (Additional
file 3B) suggests podocalyxin expression alters the fre-
quency of tumorsphere-initiating cells rather than quali-
tatively affecting sphere formation per se. Serial passage
of tumorsphere cultures is known to improve the effi-
ciency of subsequent sphere formation [26,27], and both
the shCTRL and shPODXL populations exhibited an
approximately threefold increase in the frequency of
sphere-initiating cells over three passages (Figure 1D).
To further confirm that podocalyxin has a causal role in
promoting tumorsphere formation in vitro, we overex-
pressed PODXL in MCF7 cells (MCF7Podxl) (Additional
file 3C), a luminal-like human breast cancer cell line
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lyxin [10,19]. MCF7Podxl cells (Additional file 3C) exhib-
ited a 30% increase in sphere-forming efficiency
(Figure 1E). The results of these gain- and loss-of-
function experiments suggest that podocalyxin expres-
sion increases the frequency of tumorsphere-forming
cells in these cell lines. Because formation of tumor-
spheres in suspension culture provides an estimate of
the frequency of tumor-initiating cells (TICs) [28-30],
the observation that PODXL knockdown dampens
tumorsphere formation is consistent with the notion
that podocalyxin plays a role in TIC maintenance.Podocalyxin promotes primary tumor formation and
metastasis
To examine the functional significance of podocalyxin ex-
pression in vivo, immunocompromised mice (NSG strain)
were given s.c. injections of shCTRL or shPODXL MDA-
MB-231 cells into the flank. Palpable solid tumors were
detected 8 days after injection of shCTRL MDA-MB-231
cells, and these rapidly increased in volume over time. In
comparison, growth of shPODXL MDA-MB-231 tumors
was significantly attenuated. Tumors derived from
shPODXLRFP cells were less than 250 mm3 in volume by
day 21, whereas shCTRLRFP tumors reached sizes greater
than 750 mm3 (Figure 2A, left). Similar results were
obtained in independent experiments using shCTRLGFP
and shPODXLGFP MDA-MB-231 cells (Figure 2A,
right). At the time the mice were killed, shCTRL tumors
were 2.6-fold greater in mass than shPODXL tumors
(Figure 2B). In addition, shPODXL tumors appeared to
be more encapsulated, with little to no evidence of inva-
sion into the surrounding skeletal muscle. In contrast,
shCTRL tumors were highly invasive (Figure 2C, upper
panel). Ki-67 expression was used to assess the level of
proliferation of shCTRL and shPODXL tumor cells, and
we observed a significant increase in cell proliferation
(increased number of Ki-67-stained cells) in shCTRL tu-
mors compared with shPODXL tumors (Figure 2C,
lower panel), showing that 37.6 ± 3.9% of shCTRL
tumor cells were undergoing active proliferation,
whereas no Ki-67-positive cells were detectable in
shPODXL tumors. We also examined the lungs of these
mice for signs of metastases 21 days after s.c. injection.
Although no visible tumor nodules were observed,
tumor cells were readily detectable by flow cytometry in
single-cell suspensions from the lungs. Intriguingly,
there was a 12-fold decrease in the frequency of meta-
static cells in the lungs of mice with established
shPODXL-derived primary tumors compared with mice
with shCTRL-derived primary tumors (Figure 2D). We
conclude that expression of podocalyxin enhances both
primary tumor growth and metastasis in vivo.Podocalyxin enhances the metastatic potential of breast
cancer cells
To directly examine the functional significance of podo-
calyxin expression on lung-colonizing tumor cell fre-
quency and metastatic behavior, we used an in vivo
competitive assay (experimental lung metastasis). A
50:50 mixture of shPODXL and shCTRL MDA-MB-231
cells was injected into the tail vein of NSG mice, and
relative tumor burden was evaluated at various time
points over the next 6 weeks by tracking GFP or RFP ex-
pression (that is, tumor cells), respectively. Somewhat
surprisingly, there was no significant difference in the ra-
tio of shPODXL to shCTRL cells recovered from the
lung at days 3 and 7 postinjection. However, we ob-
served a slight but significant reduction in the propor-
tion of shPODXL cells colonizing the lung by day 14
(Figure 3A). Recovered tumor cells were evaluated for
podocalyxin expression 3, 7 and 14 days after injection
into the mice. Strikingly, all shPODXL cells began to re-
express podocalyxin within 7 days of injection (likely
owing to the lack of drug selection required to maintain
shRNA expression). By day 14, shPODXL cells expressed
podocalyxin protein at levels similar to those of shCTRL
tumors (Figure 3B). A similar result was obtained with
primary solid tumors seeded s.c. in the flank (Additional
file 4). Nevertheless, at 6 weeks post i.v. injection, there
was a 2.3-fold reduction in shPODXL cell-derived tumor
nodules on the lungs compared with competing shCTRL
cell-derived tumors (Figure 3C). In addition, large, can-
cerous lesions were visible in the liver of some mice,
and, invariably, all visible liver tumors were derived from
shCTRL cells as determined by fluorescence microscopy
(Figure 3D). Subsequent flow cytometric analyses of
lung, liver and bone marrow single-cell suspensions also
revealed a dramatic under-representation of shPODXL
MDA-MB-231 cells colonizing these tissues (Figure 3E).
Thus, although podocalyxin expression on MDA-MB-
231 cells does not alter initial “seeding” of the lung at
early time points (up to 14 days), expression of podoca-
lyxin greatly enhances subsequent establishment of
clonal tumors in the lung and other organs. The similar
size of the shCTRL- and shPODXL-derived lung nodules
in these experimental assays (Additional file 5A) sug-
gests that a difference in proliferation alone cannot ac-
count for the difference in the frequency of tumor
nodules we observed. The higher frequency of shCTRL
cells in the lungs correlates (Figure 3C) with the number
of tumor nodules observed, rather than the size of the
nodules.
To further corroborate these findings and evaluate the
functional significance of podocalyxin on tumors in an
immunocompetent host, we used a syngeneic model of
tumor growth and metastasis. Using shRNA, we silenced
mouse podocalyxin surface protein expression by 6.3-
Figure 2 Podocalyxin promotes primary tumor formation, local invasion and metastasis. (A) Growth curve of subcutaneous (s.c.) flank tumors
initiated in NSG mice by scrambled shRNA control (shCTRLRFP; closed squares) or shRNA targeting PODXL (shPODXLRFP; open circles) MDA-MB-231 cells (left;
n = 5 for shCTRLRFP group and n = 6 for shPODXLRFP group; growth curves are significantly different with P < 0.001). Similarly, we compared s.c. tumor
growth of shCTRLGFP with shPODXLGFP MDA-MB-231 cells in NSG mice (right; n = 6; growth curves are significantly different with P < 0.05). GFP, Green
fluorescent protein; RFP, Red fluorescent protein. The final volume of the excised tumors was measured on the dates mice were killed (left; day 21, right;
day 20). (B) Wet weight (g) of pooled shCTRL (solid bar) and shPODXL (open bar) tumors weighed immediately after excision (n = 11 for shCTRL group
and n = 5 for shPODXL group; *P < 0.05). Representative photograph of excised shCTRL and shPODXL tumors (inset). (C) Representative H&E–stained
images of shCTRL (upper left) and shPODXL (upper right) primary tumor sections (scale bar = 1 mm). Representative immunofluorescence images of
shCTRL (lower left) and shPODXL (lower right) primary tumor sections showing Ki-67-positive cells (green). DAPI stain was used as a nuclear marker (blue).
(D) The number of tumor cells detected in the lungs 20 or 21 days after subcutaneous injection. Data shown are the number of fluorescent tumor cells
(×103) per 106 events detected by flow cytometry (n = 11 for shCTRL group and n = 5 for shPODXL group; *P < 0.05). The data shown are representative
of three independent experiments.
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mouse-derived) (Figure 4A). Similar to our results with
MDA-MB-231 cells, loss of podocalyxin expression in
4T1 cells also impaired the metastatic potential of these
cells in an experimental model of lung metastasis using
immunocompetent BALB/c mice (greater than threefold
reduction), as shown by manual counts of tumor nod-
ules on the lungs (Figure 4B) and by luciferase assays of
lung homogenates (Figure 4C). As in the MDA-MB-231
experimental metastasis assay, the frequency of tumor
nodules observed in BALB/c recipients (rather than the
size of the tumor nodules) (Figure 4B and Additional
file 5B) was affected by silencing Podxl expression in4T1 cells. Again, the total tumor cell numbers in the
lung (as measured by luciferase assay (Figure 4C)) was
proportional to the frequency of tumor nodules. Thus,
in both murine and human breast cancer cell lines,
podocalyxin expression enhances experimental meta-
static disease.
A novel podocalyxin-specific antibody prevents primary
tumor growth in vivo
The finding that podocalyxin expression is capable of driving
breast tumor progression encouraged us to evaluate the pos-
sibility that mAbs targeting the extracellular domain of
podocalyxin would prove efficacious in delaying tumor
Figure 3 Podocalyxin increases the metastatic burden in lungs, liver and bone marrow, but not initial lung seeding. (A) A 50:50 mixture of
scrambled shRNA control (shCTRL) and shRNA targeting PODXL (shPODXL) MDA-MB-231 cells were injected into the tail vein of NSG mice in a competitive
experimental metastasis model. Mice were killed 3, 7 or 14 days post-injection. Presented is the relative frequency of shCTRL and shPODXL cells detected in
the lungs by flow cytometry (as a % of total tumor cells) (n = 6; *P < 0.05). (B) Flow cytometry was performed using an antibody to detect podocalyxin
expression on tumor cells in lungs isolated from NSG mice 3, 7 and 14 days post-injection. Histograms displaying the levels of (1) surface podocalyxin
expression in shCTRLGFP cells (solid line) compared with shPODXLRFP (dashed line) cells from day 0 to day 14 (upper) and (2) surface podocalyxin expression
in shCTRLRFP (solid line) cells compared with shPODXLGFP (dashed line) cells from day 0 to day 14 (lower). The shaded day 0 histograms represent the isotype
control. RFI, Relative fluorescence intensity. (C) Representative fluorescence images of lungs showing shCTRLRFP tumor nodules (upper left) and shPODXLGFP
tumor nodules (lower left) 6 weeks post-injection. The number of fluorescent tumor nodules on the lung surface was manually counted (right; n = 5;
***P < 0.001). (D) Representative fluorescence images of livers showing shCTRLRFP tumor nodules (upper) and shPODXLGFP tumor nodules (lower) (n = 5)
6 weeks post-injection. (E) Relative frequency of shCTRL and shPODXL tumor cells within the lungs, liver and bone marrow as determined by flow
cytometry 6 weeks post-injection (n = 10; ***P < 0.001). The data shown are representative of three independent experiments. All data shown were
pooled from mice injected with shCTRLRFP versus shPODXLGFP or shCTRLGFP versus shPODXLRFP run in tandem experiments.
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172 glioblastoma cells as an immunogen, we generated a
novel panel of anti-human podocalyxin mAbs that exhibit
preferential binding to podocalyxin expressed on human
tumor cells. Of these candidates, we selected eight mAbs
(PODOC1 through PODOC8) with favorable selectivity
profiles based on flow cytometry screening of tumor celllines known to highly express podocalyxin (MDA-MB-
231, CAOV-3, A-172), tumor cell lines known to express
low levels of podocalyxin (MCF7, T47D, OVCAR-10) and
non-tumor-derived human cells known to express podo-
calyxin (human umbilical vascular endothelial cells and
HEK293 cells) (Table 1). Although we generated several
antipodocalyxin mAbs with affinity for podocalyxin
Figure 4 Podocalyxin enhances metastasis of 4T1 mammary tumor cells in a syngeneic mouse model. (A) Vector control (VC, black)
and shRNA targeting PODXL (shPODXL; dashed line) luciferase-expressing 4T1 (4T1-luc) murine mammary tumor cells were labeled with a
conjugated rat anti-mouse podocalyxin antibody and analyzed by flow cytometry to detect surface expression of podocalyxin. Rat igG2B was
used as an isotype control (shaded area). Data presented as histograms showing podocalyxin expression on VC cells compared with shPODXL
4T1-luc cells. RFI, Relative fluorescence intensity. (B) VC or shPODXL 4T1-luc cells were injected intravenously into BALB/c mice. Mice were killed
after 14 days, and visible tumor nodules on the lung were manually counted using a dissecting microscope (n = 9 and n = 8, respectively;
***P < 0.001). (C) Luciferase expression in the lungs from noninjected, VC and shPODXL 4T1-luc-injected mice was measured using a
luminometer (**P < 0.01). The data shown are representative of two independent experiments. RLU, Relative light units.
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an effect on tumor cell growth in monolayers or tumor-
sphere formation in vitro (data not shown).
Nevertheless, because podocalyxin expression appears to
predominantly affect the ability of tumor cells to colonize
tissues in vivo (rather than influencing their behavior
in vitro), we went on to evaluate the effects of these anti-
bodies in xenograft assays. Candidate mAbs were incubated
with tumor cells immediately before s.c. injection into the
flanks of recipient mice (pretreatment screen). One
antipodocalyxin mAb (PODOC1) inhibited MDA-MB-
231 growth and dissemination for 11 days (Figure 5A),
whereas the Iso and 7 other podocalyxin-binding candi-
date mAbs (PODOC2 through PODOC8) failed to signifi-
cantly alter tumor progression (Figure 5, B–H). Next, we
assessed the ability of PODOC1 to inhibit established
tumor growth (Figure 6). Cohorts of mice were treated
therapeutically with PODOC1 or control Ab beginning 14
days after tumor injection, when a palpable tumor had
already formed (s.c.). We consistently found that systemic
treatment of tumor-bearing mice with PODOC1 com-
pletely inhibited tumor growth (Figure 6A, B) and,
importantly, attenuated micrometastases to the lung
(Figure 6C). Thus, we validated podocalyxin as a critical
facilitator of tumor growth and progression and a thera-
peutic target for treatment in a preclinical model. To
confirm that PODOC1 specifically binds to podocalyxin,
Western blot analysis was performed on shCTRL and
shPODXL MDA-MB-231 cell lysates. PODOC1 detected
high levels of podocalyxin protein in shCTRL cells and sig-
nificantly less in shPODXL cells (Additional file 6A). Add-
itionally, in flow cytometric analyses, PODOC1 detectedextracellular podocalyxin on shCTRL and lower levels on
shPODXL MDA-MB-231 cells (Additional file 6B). It was
also important to determine whether PODOC1 was specific
for podocalyxin and did not bind to the closely related
family member, CD34. Utilizing CHO cells transfected
with human podocalyxin or CD34 (hCD34), PODOC1 was
found to specifically detect overexpression of podocalyxin
(Additional file 7B), whereas it failed to bind to
hCD34 (Additional file 7C) or mock-transfected CHO cells
(Additional file 7A). Thus, our data would support the
argument that the PODOC1 Ab is highly specific and
does not cross-react with a closely related sialomucin. We
conclude that antibodies targeting the appropriate epitope
on human podocalyxin can provide therapeutic benefit
in vivo.
Finally, to test the potential efficacy of PODOC1 on
late-stage metastatic disease, mice were injected s.c.
with shCTRLGFP MDA-MB-231 cells and tumors were
allowed to reach a size larger than 500 mm3 prior to
PODOC1 therapy. At this size, we find that metastatic
lesions readily develop in the lungs. PODOC1 or Iso Ab
was then administered to the mice with established tumor
burdens at days 20, 26, 29 and 32 (Additional file 8A).
Systemic treatment with PODOC1 appeared to margin-
ally slow the growth of the primary tumor, although the
difference was not statistically significant (Additional
file 8A, B). However, PODOC1 treatment resulted in a
dramatic reduction in the number of tumor nodules ob-
served on the lung surface (Additional file 8C) recov-
ered in total lung homogenates (Additional file 8D). We
conclude that PODOC1 provides a clear therapeutic
benefit, even in late-stage metastatic disease (that is,
Figure 5 Pretreatment of MDA-MB-231 cells with PODOC1 delays primary tumor development. Growth curves from days 4 to 16
(post-injection) of tumors resulting from subcutaneously injected MDA-MB-231 cells pretreated with isotype control (Iso; red) or one of eight
novel candidate antipodocalyxin antibodies (PODOC). (A) PODOC1 Ab (*p < 0.05; n = 3). (B) through (H) Growth curves for other candidate
PODOCs (PODOC2 through PODOC8; n = 3). The data shown are representative of two independent experiments.
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tumor cells).
Discussion
Although podocalyxin is expressed by a minor subset of pri-
mary breast tumors, these have been shown to be the most
aggressive and difficult-to-treat breast cancers [10]. Import-
antly, podocalyxin expression is also a predictor of poor
prognosis in many other cancers [10-15,17,18,20,31,32]. For
example, patients with podocalyxin-positive colorectal car-
cinoma (where podocalyxin-expressing cells are often lo-
cated at the invasive front of the primary tumor) have ahigher probability of lymph node and distant metastases
[31]. In addition, roughly 20% of stage III colorectal carcin-
omas express high levels of podocalyxin, and these represent
a cohort that significantly benefits from adjuvant chemo-
therapy [31]. Comparatively, similar patients with low levels
of tumor podocalyxin did not appear to significantly benefit
from chemotherapy [31]. Knowing the likelihood of success
before accepting a treatment that is difficult for some pa-
tients to tolerate has obvious decision-making benefit. Thus,
podocalyxin-based “theranostic” and therapeutic strategies
may prove to have broad applications if podocalyxin pro-
motes primary tumor growth and metastasis in colorectal
Figure 6 Systemic treatment with antipodocalyxin antibody PODOC1 inhibits primary tumor development and metastasis to the lung. (A)
Growth curve of tumors from mice treated intraperitoneally (i.p.) with 100 μg of isotype control (Iso) or antipodocalyxin monoclonal antibody (mAb) PODOC1
on day 14 and every 3 to 4 thereafter days until being killed on day 27 (n = 5; *P < 0.05 by two-way analysis of variance) (right). Orange stars indicate i.p.
administration of antibody. (B)Weight (g) of tumors treated with either Iso or PODOC1. Representative photograph shows tumors treated with either Iso or
PODOC1 (inset) (n = 5; *P = 0.05). (C) Number of red fluorescent protein (RFP)-positive tumor cells per 106 lung cells of mice with tumors treated i.p. with
either Iso or PODOC1 as detected by flow cytometry (n = 5; *P < 0.05). The data shown are representative of two independent experiments.
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to further explore the therapeutic efficacy of PODOC1 and
similar reagents in a clinical setting. Because podocalyxin is
present on normal human cells, including the vascular
endothelium and kidney podocytes, extensive toxicologic
studies will be needed to ensure the safety of a therapeutic
Ab. However, we predict that because the podocalyxin-rich
podocytes of the kidney are behind the blood filtration bar-
rier in the urinary space, they may be spared exposure to
PODOC1 therapy. Additionally, we have not observed any
adverse effect of antibodies targeting mouse podocalyxin
when systemically administered to wild-type mice. Further-
more, we have found that selective deletion of Podxl from
mouse endothelia is well tolerated and nontoxic in mice
[33]. Thus, the data would support the argument that inter-
fering with podocalyxin expression on endothelia or binding
of podocalyxin-reactive antibodies to the vasculature is un-
likely to be toxic.
By identifying a requirement for podocalyxin in tumori-
genesis, we can now begin to characterize the key molecu-
lar mechanisms by which podocalyxin promotes tumor
cell growth and colonization of supportive niches. As is
highlighted by Ki-67 staining of subcutaneous tumors,
one function of podocalyxin may be the promotion of pri-
mary tumor cell proliferation in vivo. Intriguingly, this ef-
fect was observed only in vivo because loss of podocalyxin
had no effect on the proliferation of cultured tumor cells.
Notably, although silencing podocalyxin is detrimental to
tumorsphere-forming efficiency of MDA-MB-231 cells,
the PODOC1 mAb does not appear to alter tumorsphere-
forming efficiency or proliferation in vitro (not shown).
Tumor formation and metastasis in vivo are dependent on
a number of cellular characteristics that are difficult to
mimic in vitro, including migration to and colonization ofa supportive niches, immune cell evasion, and survival of
a hypoxic environment until the establishment of an ad-
equate blood supply. It is likely that podocalyxin functions
in these settings are multifactorial, and, thus far, we have
been compelled to use in vivo models for these studies. It
is now important to evaluate the molecular pathways
podocalyxin impinges on in vivo that lead to altered tumor
cell proliferation.
With regard to the early stages of tumor colonization
of tissues, it is intriguing that the bulk of our shPODXL
cells begin to reexpress PODXL during the first 7 to 14
days in vivo. Thus, our data would support an argument
for an important influence of podocalyxin on an early
tumor-initiating subset of cells. This notion is supported
by the fact that, in our experimental lung metastasis as-
says, we found that silencing podocalyxin expression de-
creased the frequency (but not the size) of tumor
nodules we observed. In aggregate, these data suggest
that even transient depletion of podocalyxin expression
during the early phase of tumor establishment can have
a profound effect on late-stage growth of metastases,
perhaps through impaired function or decreased fre-
quency of a population of cells with TIC-like properties.
We do not yet know which properties of TICs are influ-
enced by podocalyxin expression, but they could include
properties that enable tumor cells to proliferate or
survive within a metastatic niche, including invasion,
migration, adhesion and recruitment of supportive
vasculature. It is noteworthy that podocalyxin, and its
close relative CD34, are well-known markers of various
subsets of stem cells during development and play a role
in cell and tissue morphogenesis and colonization of de-
veloping tissues [7,9,26,27,31]. Likewise, podocalyxin
was recently detected in an undifferentiated stemlike
Snyder et al. Breast Cancer Research  (2015) 17:46 Page 12 of 14population in glioblastoma multiforme [11], and it is a
well-known marker of both embryonic stem cells and
embryocarcinomas [3,6]. Thus, in both normal develop-
ment and neoplastic disease, podocalyxin expression has
been linked to stem cell activity. Impaired tumor initiation
would be consistent with known roles for podocalyxin and
CD34-type proteins in blocking cell adhesion and facilitat-
ing chemokine-dependent inflammatory trafficking and
hematopoietic stem cell engraftment of the bone marrow
niche [34-36]. Importantly, in contrast to the wide variety
of drugs that target tumor proliferation, there is a paucity
of therapeutics that target TIC activity, and therefore the
Ab strategy described here may be an important add-
itional therapeutic avenue.
In many ways, our findings are complementary to
those described in a recent publication by Lin et al.
[37]. These authors provided provocative evidence that
both podocalyxin and cortactin are important for the
morphogenesis, motility, gelatin invasion and in vivo
metastatic potential of MDA-MB-231 cells and showed
that these proteins associate in vitro. Although they did not
show that podocalyxin is essential for cortactin-mediated
metastasis in vivo, these data do offer a potential mechanis-
tic insight into podocalyxin function through a cortactin-
containing complex. Given that our present study shows
podocalyxin to be functionally important for tumorsphere-
forming cells in vitro and the early phases of tumor
colonization by a subset of cells in vivo, it is now important
to validate the functional significance of the cortactin and
podocalyxin interaction in this rare, but clinically critical,
subset of tumor cells.
Conclusions
It has previously been shown that podocalyxin expres-
sion in invasive breast carcinoma correlates with poor
patient survival and that podocalyxin enhances the mo-
tility and invasiveness of breast cancer cell lines in vitro
[10,19-21]. Here, using in vivo models of breast tumor
growth and metastasis, we show that podocalyxin has a
causal role in promoting the growth and proliferation of
solid tumors and enhancing the metastasis of tumor
cells to distant organs. We found that silencing podoca-
lyxin expression in MDA-MB-231 cells, an aggressive
triple-negative, basal-like breast cancer cell line, se-
verely impaired primary tumor growth and metastasis
to the lung, liver and bone marrow in a xenograft
model. We corroborated these results in a syngeneic
mouse model using fully immunocompetent mice by
silencing podocalyxin expression in mouse mammary
tumor 4T1 cells. Thus, in both mouse and human breast
tumor cells, podocalyxin plays a critical role in disease
progression. Furthermore, we have developed a unique
mAb that targets podocalyxin and, in preclinical mouse
studies, inhibits tumor growth and metastatic progression.Additional files
Additional file 1: Podocalyxin expression can be efficiently knocked
down in MDA-MB-231 cells. shCTRL and shPODXL MDA-MB-231
whole-cell lysates (5 × 104 cells) were resolved by SDS-PAGE and
analyzed by Western blotting using antipodocalyxin clone 3D3
(1:4,000; Santa Cruz Biotechnologies, Santa Cruz, CA, USA). An antibody
against β-actin (1:10,000; Sigma-Aldrich) was used as a loading control.
Additional file 2: Proliferation is not affected by podocalyxin
expression in MDA-MB-231 cells in monolayer culture. A 3-(4,5-
dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-
tetrazolium proliferation assay was performed on shCTRL and shPODXL
MDA-MB-231 cells 48, 72 and 96 hours after initial seeding. Proliferation
was quantified by the amount of formazan product detected at 490-nm
absorbance using a microplate reader. The level of proliferation of shCTRL
was compared with shPODXL cells over time (nonsignificant by two-way
analysis of variance). All values are graphed as mean ± SEM.
Additional file 3: shCTRL and shPODXL cells form tumorspheres
of similar size and morphology. A total of 5 × 103 shCTRL or shPODXL
MDA-MB-231 cells were cultured for 7 days in MammoCult medium.
(A) Tumorsphere size was calculated using ImageJ software (pixels).
(B) Representative images of shCTRL and shPODXL MDA-MB-231
tumorspheres. (C) Murine podocalyxin expression can be overexpressed
in human MCF7 breast tumor cells. MCF7pIRES control and MCF7Podxl
lysates were resolved by SDS-PAGE and analyzed by Western blotting
using a goat anti-mouse podocalyxin antibody (1 μg/ml; R&D Systems).
An antibody against β-actin was used as a loading control. (D) Flow
cytometry was performed to detect the level of extracellular murine
podocalyxin on MCF7pIRES (left; blue) and MCF7Podxl cells (right; red). A
goat anti-mouse podocalyxin antibody (2.5 μg/106 cells; R&D Systems)
and an isotype against normal goat IgG (gray) were used.
Additional file 4: Podocalyxin is reexpressed in primary MDA-MB-
231 tumors after 14 days in vivo. A total of 1 × 106 shCTRLGFP or
shPODXLGFP MDA-MB-231 cells were injected s.c. into the right and left
flanks of NSG mice. After 14 days, mice were killed and perfused with 10
ml of ice-cold PBS, and tumors were excised. (A) One-third of each
shCTRL and shPODXL tumor was processed for flow cytometric analysis
using a 2-U/ml collagenase solution for 1 hour at 37°C and stained for
extracellular podocalyxin using one of two antibodies (PODOC1 or goat
antihuman podocalyxin; R&D Systems). The upper two histograms display
the level of surface podocalyxin expression in shCTRLGFP cells (left; blue)
compared with shPODXLGFP cells (right, blue) as detected by PODOC1
antibody. A goat antihuman AF647 (2 μg/ml; Invitrogen) secondary-only
control is shown in red. The lower two histograms display the level of
surface podocalyxin expression in shCTRLGFP cells (left; blue) compared with
shPODXLGFP cells (right; blue) as detected by goat antihuman podocalyxin
(2 μg/ml; R&D Systems) followed by chicken anti-goat AF647 (Invitrogen).
Normal goat IgG isotype control is shown in red. (B) One-third of the tumors
were processed “fresh” for Western blot analysis by directly homogenizing
them in 500 μl of radioimmunoprecipitation assay (RIPA) lysis buffer, and the
final third of the tumors were freeze-thawed (F/T) by snap-freezing in dry
ice and storing them at −80°C for 1 hour. F/T tumors were homogenized in
500 μl of RIPA lysis buffer. A BCA assay was performed, and equal amounts
of protein were resolved by SDS-PAGE and analyzed by Western blotting
using antipodocalyxin clone 3D3 (1:4,000; Santa Cruz Biotechnologies). An
antibody against β-actin (1:10,000; Sigma-Aldrich) was used as a loading
control.
Additional file 5: Metastatic lung nodules resulting from MDA-MB-
231 cells or 4D1 cells are more prevalent in number, but not of
greater size when compared with their respective podocalyxin
knockdown lines. (A) NSG mice were injected (i.v.) with a 50:50 mixture
of shCTRLGFP and shPODXLRFP MDA-MB-231 cells (5 × 104 cells). After 6
weeks, mice were killed and their lungs and fluorescent nodules on the
lungs were imaged using a fluorescence dissecting microscope. The GFP
and RFP channels were merged as a composite image to show nodules
arising from both shCTRL and shPODXL cells. (B) BALB/c mice were
injected (i.v.) with 1 × 105 vector control (VC) or shPodxl mouse murine
4D1 tumor cells. After 2 weeks, lungs were perfused with ice-cold PBS,
fixed in 10% buffered formalin, embedded in paraffin and sectioned.
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stained with H&E.
Additional file 6: PODOC1 antibody specifically detects podocalyxin
expression in MDA-MB-231 cells. (A) shCTRL and shPODXL MDA-MB-231
whole-cell lysates were resolved by SDS-PAGE and analyzed by Western
blotting using candidate therapeutic antibody PODOC1 (1 μg/ml). An
antibody against β-actin was used as a loading control. (B) Podocalyxin
expression on shCTRLGFP (solid) and shPODXLGFP (dashed) MDA-MB-231
cells relative to secondary-only control (shaded), as detected using PODOC1
(10 μg/ml) antibody followed by goat antihuman AF647 secondary antibody
(2 μg/ml; Invitrogen) (right).
Additional file 7: PODOC1 antibody specifically interacts with
podocalyxin and does not bind to CD34. Human CD34 (hCD34) and
podocalyxin were transiently overexpressed in CHO cells. Flow cytometry
was performed on CHO cells transfected with (A) human podocalyxin
(CHOPODXL) or (B) human CD34 (CHOhCD34) or (C) mock sequence
(CHOMock) and stained with either PODOC1 (left) (10 μg/ml) or mouse
antihuman CD34 fluorescein isothiocyanate–conjugated antibody (right)
(1:50; Invitrogen).
Additional file 8: Systemic treatment with PODOC1 inhibits
metastasis to the lung in mice with large (>500 mm3) primary
MDA-MB-231 tumors. A total of 1 × 106 shCTRLGFP MDA-MB-231 cells
were injected s.c. into the flank of NSG mice and allowed to develop into
solid tumors over 20 days. (A) Growth curve of tumors from mice treated
intraperitoneally (i.p.) with 4.5 mg/kg of isotype control (Iso) or PODOC1
Ab on day 20 and at three time points until the mice were killed on day
36 (nonsignificant (n.s.) by two-way analysis of variance; n = 5) (right).
Orange stars indicate i.p. administration of antibody. (B) Weight (g) of
tumors treated with either Iso or PODOC1 antibody (n = 5; n.s. by
Student’s t-test). (C) Representative bright-field and fluorescence
microscopic images of lungs showing shCTRLGFP tumor nodules from
mice that had been systemically treated with Iso (upper two panels) or
PODOC1 (lower two panels). (D) Percentage of GFP-positive tumor cells
in the lungs of mice with tumors treated i.p. with either isotype or
PODOC1 antibody as detected by flow cytometry (n = 5; *P < 0.05).
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